Business
ALNOV: EBITDA loss narrowed, cash remains strong, and reproductive health drives growth
ALNOV: EBITDA loss narrowed, cash remains strong, and reproductive health drives growth
About this update from Novacyt Sas
Revenue for H1 2025 was £9.8m, with EBITDA loss narrowing to £4.1m and cash at £23.7m. Strong growth in reproductive health, especially NIPT, and successful launch of LightBench® Discover support a positive outlook, with management confident in reaching EBITDA profitability. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.